BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Xiaoyan Yang, Peng Feng, Xiangjian Zhang, Dongfang Li, Ruifang Wang, Chenhui Ji, Guanglai Li, Christian Hölscher. The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of strokeNeuropharmacology 2019; 158: 107748 doi: 10.1016/j.neuropharm.2019.107748
2
Neil Skolnik, Renell S. Dupree, Eric L. Johnson. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agentsCurrent Medical Research and Opinion 2017; 33(12): 2187 doi: 10.1080/03007995.2017.1359518
3
Gerhard H. Scholz, Holger Fleischmann. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingTherapeutic Advances in Endocrinology and Metabolism 2014; 5(5): 95 doi: 10.1177/2042018814556099
4
Tina Vilsbøll, Jiten Vora, Henrik Jarlov, Kajsa Kvist, Lawrence Blonde. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given AloneClinical Drug Investigation 2016; 36(4): 293 doi: 10.1007/s40261-016-0376-0
5
Paula L. McClean, Christian Hölscher. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's diseaseNeuropharmacology 2014; 86: 241 doi: 10.1016/j.neuropharm.2014.07.015
6
Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes, Flávio Reis. The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?Journal of Diabetes Research 2015; 2015: 1 doi: 10.1155/2015/806979
7
Sarah L. Greig, Lesley J. Scott. Insulin Degludec/Liraglutide: A Review in Type 2 DiabetesDrugs 2015; 75(13): 1523 doi: 10.1007/s40265-015-0448-0
8
Mie Tonoike, Daisuke Chujo, Mitsuhiko Noda. Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetesEndocrinology, Diabetes & Metabolism 2019; 2(1): e00043 doi: 10.1002/edm2.43
9
Jennifer D. Goldman-Levine. Combination Therapy When Metformin Is Not an Option for Type 2 DiabetesAnnals of Pharmacotherapy 2015; 49(6): 688 doi: 10.1177/1060028015572653
10
Takahisa Hirose, Manabu Suzuki, Isao Tsumiyama. Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized StudyDiabetes Therapy 2015; 6(4): 559 doi: 10.1007/s13300-015-0147-6
11
Shigeo Fuji, Sung-Won Kim, Shigemi Kamiya, Takahiko Nakane, Kenji Matsumoto, Yasushi Onishi, Kimikazu Yakushijin, Etsuko Yamazaki, Masayuki Hino, Saiko Kurosawa, Ken-ichi Yoshimura, Takahiro Fukuda. A multi-center prospective study randomizing the use of fat emulsion in intensive glucose control after allogeneic hematopoietic stem cell transplantation using a myeloablative conditioning regimenClinical Nutrition 2018; 37(5): 1534 doi: 10.1016/j.clnu.2017.08.022
12
Bo Ahrén. Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?Diabetologia 2015; 58(8): 1740 doi: 10.1007/s00125-015-3557-0
13
Richard Simpson, Allen King. Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?Expert Review of Clinical Pharmacology 2015; 8(2): 179 doi: 10.1586/17512433.2015.1017562
14
Marcus Lind, Irl B. Hirsch, Jaakko Tuomilehto, Sofia Dahlqvist, Ole Torffvit, Nils-Gunnar Pehrsson. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial)Primary Care Diabetes 2015; 9(1): 15 doi: 10.1016/j.pcd.2014.07.010
15
Andrea Tura, Johan Farngren, Anja Schweizer, James E. Foley, Giovanni Pacini, Bo Ahrén. Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and VildagliptinInternational Journal of Endocrinology 2015; 2015: 1 doi: 10.1155/2015/484231
16
Lisa J. Underland, Jeniece Trast Ilkowitz, Ranjitha Katikaneni, Amy Dowd, Rubina A. Heptulla. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 DiabetesJournal of Diabetes Science and Technology 2017; 11(3): 602 doi: 10.1177/1932296817699847
17
Jennifer Goldman, Jennifer M. Trujillo. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 DiabetesAnnals of Pharmacotherapy 2017; 51(11): 990 doi: 10.1177/1060028017717281
18
Aline Haas de Mello, Morgana Prá, Larissa Colonetti Cardoso, Rosiane de Bona Schraiber, Gislaine Tezza Rezin. Incretin-based therapies for obesity treatmentMetabolism 2015; 64(9): 967 doi: 10.1016/j.metabol.2015.05.012
19
Yasuo Terauchi, Yusuke Naito, Yukio Ikeda. Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patientsDiabetes & Metabolic Syndrome: Clinical Research & Reviews 2016; 10(1): 23 doi: 10.1016/j.dsx.2015.08.008
20
Cristina Mega, Edite Teixeira-de-Lemos, Rosa Fernandes, Flávio Reis. Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 DiabetesJournal of Diabetes Research 2017; 2017: 1 doi: 10.1155/2017/5164292
21
S Fuji, A Rovó, K Ohashi, M Griffith, H Einsele, M Kapp, M Mohty, N S Majhail, B G Engelhardt, A Tichelli, B N Savani. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCTBone Marrow Transplantation 2016; 51(8): 1041 doi: 10.1038/bmt.2016.81
22
André J Scheen. A review of gliptins for 2014Expert Opinion on Pharmacotherapy 2015; 16(1): 43 doi: 10.1517/14656566.2015.978289
23
Lyudmila Alexandrovna Ruyatkina, Maxim Sorokin. Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an allianceDiabetes mellitus 2017; 20(2): 142 doi: 10.14341/7875
24
Bo Ahrén. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug developmentJournal of Diabetes Investigation 2019; 10(2): 196 doi: 10.1111/jdi.12911
25
B. Ahrén. Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose controlDiabetes & Metabolism 2015; 41(6): 6S3 doi: 10.1016/S1262-3636(16)30002-7
26
Yeong Gi Kim, Se Hee Min, Seokyung Hahn, Tae Jung Oh, Kyong Soo Park, Young Min Cho. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysisDiabetes Research and Clinical Practice 2016; 116: 86 doi: 10.1016/j.diabres.2016.03.011
27
Johan Farngren, Bo Ahrén. Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodesMetabolism 2019; 99: 25 doi: 10.1016/j.metabol.2019.06.016
28
Andrew J. Krentz, Christian Weyer, Marcus Hompesch. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease2019; : 75 doi: 10.1007/978-3-030-11748-1_3
29
Arun K. Sharma, Punniyakoti V. Thanikachalam, Satyendra K. Rajput. Albiglutide: Is a better hope against diabetes mellitus?Biomedicine & Pharmacotherapy 2016; 77: 120 doi: 10.1016/j.biopha.2015.12.015
30
R. G. Lentle, I. R. Sequeira, A. K. Hardacre, G. Reynolds. A method for assessing real time rates of dissolution and absorption of carbohydrate and other food matrices in human subjectsFood & Function 2016; 7(6): 2820 doi: 10.1039/C6FO00406G
31
Uchenna Anyanwagu, Jil Mamza, Richard Donnelly, Iskandar Idris. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort studyAmerican Heart Journal 2018; 196: 18 doi: 10.1016/j.ahj.2017.10.003
32
John C. Clapham. Type 2 DiabetesMethods in Molecular Biology 2020; 2076: 1 doi: 10.1007/978-1-4939-9882-1_1
33
Manel Mata-Cases, Dídac Mauricio, Josep Franch-Nadal. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targetsJournal of Diabetes 2017; 9(1): 34 doi: 10.1111/1753-0407.12373
34
Ohad Cohen, Sebastiano Filetti, Javier Castañeda, Marianna Maranghi, Mariela Glandt. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin PumpDiabetes Care 2016; 39(Supplement 2): S180 doi: 10.2337/dcS15-3029